Altomare, Daniele http://orcid.org/0000-0003-1905-8993
Molinuevo, José Luis
Ritchie, Craig
Ribaldi, Federica
Carrera, Emmanuel
Dubois, Bruno
Jessen, Frank
McWhirter, Laura
Scheltens, Philip
van der Flier, Wiesje M.
Vellas, Bruno
Démonet, Jean-François
Frisoni, Giovanni B.
,
Abramowicz, Marc
Altomare, Daniele
Barkhof, Frederik
Berthier, Marcelo
Bieler, Melanie
Blennow, Kaj
Brayne, Carol
Brioschi, Andrea
Carrera, Emmanuel
Chételat, Gael
Csajka, Chantal
Demonet, Jean-François
Dodich, Alessandra
Dubois, Bruno
Frisoni, Giovanni B.
Garibotto, Valentina
Georges, Jean
Hurst, Samia
Jessen, Frank
Kivipelto, Miia
Llewellyn, David
McWhirter, Laura
Milne, Richard
Minguillón, Carolina
Miniussi, Carlo
Molinuevo, José Luis
Nilsson, Peter M.
Ranson, Janice
Ribaldi, Federica
Ritchie, Craig
Scheltens, Philip
Solomon, Alina
van Der Flier, Wiesje
van Duijn, Cornelia
Vellas, Bruno
Visser, Leonie
Funding for this research was provided by:
Swiss National Science Foundation (IZSEZ0_193593)
Article History
Received: 14 January 2021
Accepted: 12 April 2021
First Online: 11 October 2021
Change Date: 23 October 2021
Change Type: Update
Change Details: The paper was amended to add a DOI in references part of the Brain Health Services series.
Declarations
:
: Not applicable.
: Not applicable.
: JLM is currently a full-time employee of Lundbeck and has previously served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences.BD has received research funding (paid to the institution) from Merck-Avenir Foundation, Roche and consultancy fees from Biogen, Neurodiem, Green Valley, Cytox, Brainstorm. He is PI of clinical trials with EISAI, Genentech, Novartis, Biogen, Roche.PS has received consultancy fees (paid to the institution) from AC Immune, Alkermes, Alnylam, Anavex, Biogen, Brainstorm Cell, Cortexyme, Denali, EIP, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Noridisk, PeopleBio, Renew LLC, Roche. He is PI of studies with AC Immune, CogRx, FUJI-film/Toyama, IONIS, UCB, Vivoryon. He serves on the board of the Brain Research Center.WMvdF has received consultancy fees (paid to the institution) from Oxford Health Policy Forum CIC, Roche BV. She has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc., and WebMD Neurology (Medscape). She has performed contract research for Biogen MA Inc. and Boehringer Ingelheim. All funding is paid to her institution. WF is associate editor at <i>Alzheimer’s Research & Therapy</i>.JFD has received consultancy fees from Biogen and OM Pharma; unrestricted grants from OM Pharma; and has collaboration agreements with Siemens and MindMaze.GBF reports grants from Alzheimer Forum Suisse, Académie Suisse des Sciences Médicales, Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, Association Suisse pour la Recherche sur l’Alzheimer, IXICO, Merz Pharma, Nestlé, Novartis, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, Vifor Pharma, and Alzheimer’s Association; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics.The other coauthors declare that they have no competing interests.